Global Postmenopausal Osteoporosis Drugs Market 2016-2020

Table of Contents

PART 01: Executive summary

• Highlights

PART 02: Scope of  the report

• Market overview
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights

PART 05: Disease overview

• Understanding postmenopausal osteoporosis
• Epidemiology and demography
• Risk factors
• Symptoms
• Diagnosis
• Treatment

PART 06: Key buying criteria

PART 07: Pipeline scenario

• TBRIA
• Romosozumab (AMG785)
• Odanacatib (MK-0822)
• Abaloparatide SC/Abaloparatide transdermal patch
• PHN-031 (PH3)
• NB S101
• Teriparatide ZP Patch (ZP-PTH)
• Blosozumab (LY2541546)

PART 08: Market landscape

• Market overview
• Market size and forecast
• Five forces analysis

PART 09: Market segmentation by therapeutic class

• Antiresorptive medications
• Anabolic medications

PART 10: Market segmentation by line of therapy

PART 11: Geographical segmentation

• Global postmenopausal osteoporosis drugs market by geographical segmentation 2015-2020
• Postmenopausal osteoporosis drugs market in Americas
• Postmenopausal osteoporosis drugs market in EMEA
• Postmenopausal osteoporosis drugs market in APAC

PART 12: Market drivers

• Increase in older population
• Growing prevalence of postmenopausal osteoporosis
• Expected launch of promising pipeline molecules
• High unmet medical needs

PART 13: Impact of drivers

PART 14: Market challenges

• Multiple patent expiries
• Low diagnosis rate
• Nonadherence to treatment regimen
• Drug reimbursement issues

PART 15: Impact of drivers and challenges

PART 16: Market trends

• Awareness programs and initiatives
• Emergence of novel agents
• Emergence of combination therapies

PART 17: Vendor landscape

• Competitive scenario
• Market analysis 2015
• Eli Lilly
• Amgen
• Merck
• Novartis
• Other prominent vendors

PART 18: Appendix

• List of abbreviations

PART 19: Explore Technavio